Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 17/20 | 0.53 |
| ▸ | QPCTL | Q9NXS2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1673351 | 1.00 | QPCT (0.53) | QPCTQPCTLALDH1A1LMNACCR5 | |
| SCHEMBL1444538 | 0.92 | QPCT (0.56) | QPCTQPCTLALDH1A1LMNA | |
| SCHEMBL1444426 | 0.85 | QPCT (0.54) | QPCTQPCTLALDH1A1 | |
| SCHEMBL29410593 | 0.84 | QPCT (0.53) | QPCTQPCTLALDH1A1 | |
| SCHEMBL1673327 | 0.84 | QPCT (0.53) | QPCTQPCTLALDH1A1 | |
| SCHEMBL12812830 | 0.78 | QPCT (0.42) | QPCTQPCTL | |
| SCHEMBL12733047 | 0.78 | QPCT (0.42) | QPCTQPCTL | |
| Varoglutamstat SCHEMBL29359228 | 0.77 | QPCT (0.85) | QPCTQPCTL | |
| Varoglutamstat SCHEMBL1445235 | 0.77 | QPCT (0.85) | QPCTQPCTL | |
| Varoglutamstat SCHEMBL29410462 | 0.77 | QPCT (0.85) | QPCTQPCTL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3658141-B1 | TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPALPHA - CD47 INTERACTION | STICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) | 2022-11-16 | — | — | EP | claimed |
| US-20220087981-A1 | TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA-CD47 INTERACTION | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis (NL) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220087981-A1 | TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA-CD47 INTERACTION | QPCT, QPCTL, CD47 | QPCT 1/4885QPCTL 2/4885ALDH1A1 3827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.